Who
William P. Kane Jr.
Director
Company insider
Files Form 4 as: Director, LB Pharmaceuticals; Chief Commercial Officer, Karuna Therapeutics; Chief Commercial Officer, BioXcel Therapeutics.
In numbers
- Trades disclosed
- 13
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 15 Jun 2020
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 10 Sep 2025filed 12 Sep 2025 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,449 at $0.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $3.4M10,306 at $330.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $4.1M29,937 at $137.85 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeutics | SEC FORM 4 Code D | $1.6M5,000 at $330.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeutics | SEC FORM 4 Code D | $2.9M8,828 at $330.00 | filing |
| 13 Feb 2024filed 15 Feb 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,306 at $0.00 | filing |
| 28 Dec 2023filed 29 Dec 2023 | Karuna Therapeutics | SEC FORM 4 Code F | $1.2M3,828 at $316.30 | filing |
| 6 Feb 2023filed 7 Feb 2023 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code A | —29,937 at $0.00 | filing |
| 6 Feb 2023filed 7 Feb 2023 | Karuna Therapeutics | SEC FORM 4 Code A | —17,656 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 15 Jun 2020filed 17 Jun 2020 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.